GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » Cyclically Adjusted PS Ratio

Enzo Biochem (Enzo Biochem) Cyclically Adjusted PS Ratio : 0.51 (As of Apr. 29, 2024)


View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem Cyclically Adjusted PS Ratio?

As of today (2024-04-29), Enzo Biochem's current share price is $1.06. Enzo Biochem's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2024 was $2.07. Enzo Biochem's Cyclically Adjusted PS Ratio for today is 0.51.

The historical rank and industry rank for Enzo Biochem's Cyclically Adjusted PS Ratio or its related term are showing as below:

ENZ' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.48   Med: 1.32   Max: 4.64
Current: 0.51

During the past years, Enzo Biochem's highest Cyclically Adjusted PS Ratio was 4.64. The lowest was 0.48. And the median was 1.32.

ENZ's Cyclically Adjusted PS Ratio is ranked better than
83.82% of 136 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.235 vs ENZ: 0.51

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Enzo Biochem's adjusted revenue per share data for the three months ended in Jan. 2024 was $0.169. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.07 for the trailing ten years ended in Jan. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Enzo Biochem Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Enzo Biochem's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem Cyclically Adjusted PS Ratio Chart

Enzo Biochem Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.55 0.99 1.33 0.99 0.68

Enzo Biochem Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 1.11 0.68 0.63 0.61

Competitive Comparison of Enzo Biochem's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Enzo Biochem's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Enzo Biochem's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Enzo Biochem's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Enzo Biochem's Cyclically Adjusted PS Ratio falls into.



Enzo Biochem Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Enzo Biochem's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.06/2.07
=0.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzo Biochem's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2024 is calculated as:

For example, Enzo Biochem's adjusted Revenue per Share data for the three months ended in Jan. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=0.169/129.4194*129.4194
=0.169

Current CPI (Jan. 2024) = 129.4194.

Enzo Biochem Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201404 0.554 100.023 0.717
201407 0.565 100.520 0.727
201410 0.557 100.176 0.720
201501 0.513 98.604 0.673
201504 0.524 99.824 0.679
201507 0.558 100.691 0.717
201510 0.545 100.346 0.703
201601 0.528 99.957 0.684
201604 0.572 100.947 0.733
201607 0.565 101.524 0.720
201610 0.568 101.988 0.721
201701 0.567 102.456 0.716
201704 0.584 103.167 0.733
201707 0.548 103.278 0.687
201710 0.573 104.070 0.713
201801 0.557 104.578 0.689
201804 0.536 105.708 0.656
201807 0.482 106.324 0.587
201810 0.451 106.695 0.547
201901 0.409 106.200 0.498
201904 0.413 107.818 0.496
201907 0.438 108.250 0.524
201910 0.425 108.577 0.507
202001 0.408 108.841 0.485
202004 0.354 108.173 0.424
202007 0.409 109.318 0.484
202010 0.598 109.861 0.704
202101 0.655 110.364 0.768
202104 0.672 112.673 0.772
202107 0.510 115.183 0.573
202110 0.547 116.696 0.607
202201 0.702 118.619 0.766
202204 0.538 121.978 0.571
202207 -1.111 125.002 -1.150
202210 0.146 125.734 0.150
202301 0.154 126.223 0.158
202304 0.326 127.992 0.330
202307 -0.395 128.974 -0.396
202310 0.156 129.810 0.156
202401 0.169 129.419 0.169

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Enzo Biochem  (NYSE:ENZ) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Enzo Biochem Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Enzo Biochem (Enzo Biochem) Business Description

Traded in Other Exchanges
Address
527 Madison Avenue, New York, NY, USA, 10022
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.
Executives
Steven J Pully director 9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042
James G. Wolf 10 percent owner 105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455
Hamid Erfanian officer: Chief Executive Officer 527 MADISON AVENUE, NEW YORK NY 10022
Patricia Eckert officer: Interim CFO C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735
Kara Cannon officer: Chief Operating Officer 527 MADISON AVE, NEW YORK NY 10022
Bradley Louis Radoff director 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
David Bench officer: CHIEF FINANCIAL OFFICER ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Harbert Discovery Fund, Lp 10 percent owner HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Ian B. Walters director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Mary Tagliaferri director 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Clemens Peter J Iv 10 percent owner 2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069
Rebecca J. Fischer director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Fabian Blank 10 percent owner, other: See Remarks ROEMERSTRASSE 6, BAD BERTRICH 2M 56864
Harbert Management Corp 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Harbert Discovery Co-investment Fund I Gp, Llc 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203